Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $52.77

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned an average rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $52.7692.

A number of research firms recently commented on CLDX. UBS Group lifted their target price on Celldex Therapeutics from $38.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. Wall Street Zen upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Canaccord Genuity Group reduced their price target on shares of Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Wells Fargo & Company decreased their price objective on shares of Celldex Therapeutics from $54.00 to $48.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. Finally, Guggenheim lifted their price objective on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Monday, July 20th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CLDX. Wilmington Savings Fund Society FSB purchased a new stake in Celldex Therapeutics in the third quarter valued at $42,000. Russell Investments Group Ltd. grew its position in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP acquired a new stake in Celldex Therapeutics during the 3rd quarter worth about $63,000. Kestra Advisory Services LLC purchased a new position in shares of Celldex Therapeutics during the 4th quarter valued at about $98,000. Finally, Headlands Technologies LLC acquired a new position in shares of Celldex Therapeutics in the 2nd quarter valued at about $125,000.

Celldex Therapeutics Stock Performance

Shares of CLDX opened at $35.58 on Friday. The stock has a 50-day moving average of $33.86 and a two-hundred day moving average of $30.83. Celldex Therapeutics has a one year low of $19.72 and a one year high of $40.30. The stock has a market cap of $2.79 billion, a P/E ratio of -8.35 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.80 million. Analysts predict that Celldex Therapeutics will post -4.36 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.